X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://endpts.com/seagens-former-commercial-chief-joins-the-board-at-healthcare-agency-minds-assembly/
https://www.fiercepharma.com/pharma/seagen-depicts-tukysa-value-roche-adc-breast-cancer-fda-path-remains-unclear
https://www.fiercepharma.com/pharma/seagens-breast-cancer-drug-tukysa-boosts-roches-kadcyla-and-pfizers-43b-buyout
https://www.businesswire.com/news/home/20221222005382/en/Seagen-Announces-FDA-Accelerated-Approval-of-TUKYSA%C2%AE-tucatinib-in-Combination-with-Trastuzumab-for-People-with-Previously-Treated-RAS-Wild-Type-HER2-Positive-Metastatic-Colorectal-Cancer
https://endpts.com/seagen-secures-a-speedy-fda-review-on-tukysa-as-merck-buyout-talks-reportedly-stall/
https://www.fiercepharma.com/pharma/seagens-potential-breast-cancer-blockbuster-tukysa-shows-promise-colorectal-cancer
https://health.economictimes.indiatimes.com/news/pharma/south-korea-approves-phase-3-clinical-trials-of-breast-cancer-treatment-tucatinib/90931926
http://www.pharmafile.com/news/608613/nice-draft-guidance-recommends-tucatinib-advanced-breast-cancer
https://trialsitenews.com/pieris-pharmaceuticals-announces-first-patient-dosed-phase-2-gastric-cancer-trial-evaluating-4-1bb-her2-bispecific-cinrebafusp-alfa/
https://www.europeanpharmaceuticalreview.com/news/164614/nice-does-not-recommend-tucatinib-in-new-draft-guidance/
https://www.biospace.com/article/releases/seagen-announces-long-term-results-from-tukysa-tucatinib-pivotal-trial-in-patients-with-her2-positive-breast-cancer-during-the-virtual-scientific-program-of-the-2021-asco-annual-meeting/
http://www.pharmatimes.com/news/mhra_approves_seagens_tukysa_for_her2-positive_breast_cancer_1363895
http://www.pharmatimes.com/news/eu_approves_tukysa_combo_for_advanced_her2-positive_breast_cancer_1363629
https://www.onclive.com/view/tucatinib-approved-in-europe-for-locally-advanced-or-metastatic-her2-breast-cancer
https://www.businesswire.com/news/home/20201211005284/en/Seagen-Announces-Positive-CHMP-Opinion-for-TUKYSA%C2%AE-tucatinib-for-the-Treatment-of-Patients-with-Locally-Advanced-or-Metastatic-HER2-Positive-Breast-Cancer
https://www.businesswire.com/news/home/20201208005451/en/Seagen-Highlights-TUKYSA%C2%AE-tucatinib-Data-in-Breast-Cancer-at-Virtual-2020-San-Antonio-Breast-Cancer-Symposium
https://www.businesswire.com/news/home/20201029006128/en/Seagen-Reports-Third-Quarter-2020-Financial-Results#:~:text=Revenues%3A%20Total%20revenues%20for%20the,the%20same%20periods%20in%202019.
https://www.pharmtech.com/view/merck-announces-two-oncology-collaborations-with-seattle-genetics
https://investor.seattlegenetics.com/press-releases/news-details/2020/Seattle-Genetics-Announces-Positive-Results-from-Exploratory-Analyses-of-HER2CLIMB-for-TUKYSA-tucatinib-in-Brain-Metastases-Patients-With-HER2-Positive-Breast-Cancer/default.aspx
https://www.businesswire.com/news/home/20200512005217/en/Seattle-Genetics-Announces-Approval-TUKYSA%E2%84%A2-tucatinib-Switzerland
https://www.fiercepharma.com/pharma/seattle-genetics-breaks-into-breast-cancer-new-approval-tukysa
https://www.raps.org/news-and-articles/news-articles/2020/4/fda-approves-first-new-drug-under-project-orbis
https://endpts.com/seattle-genetics-gets-another-drug-close-to-the-finish-line/
https://www.fiercebiotech.com/biotech/after-sabcs-stunner-seattle-nabs-fda-breakthrough-tag-for-tucatinib
https://www.fiercebiotech.com/biotech/sabcs-seattle-genetics-hails-stunning-tucatinib-breast-cancer-data
https://xconomy.com/seattle/2019/10/21/seagen-to-seek-fda-nod-after-breast-cancer-drug-hits-goals-of-key-study/
https://www.fiercebiotech.com/biotech/seattle-genetics-breast-cancer-drug-hits-mark-pivotal-trial
https://www.biopharmadive.com/news/seattle-genetics-esmo-data-enfortumab-vedotin-bladder-cancer/563995/
Market Place
Share 
